Moreover, higher inhibition of imatinib resistant BaF3/bcr-abl/T315I than K562 by C3 exoenzyme suggested that rhoA could be a good therapeutic target in CML. This evidence concerns the gene RHOA and chronic myelogenous leukemia, BCR-ABL1 positive.